An intrauterine G-CSF instillation procedure (GIP) is a treatment for poor development of the lining of the uterus during assisted reproduction treatment cycles (<7mm) that is resistant to other treatments. It involves the injection into the uterine cavity of Nivestim™ in a procedure that is technically the same as an intrauterine insemination procedure and very similar to an embryo transfer procedure.
Granulocyte Colony Stimulating Factor (G-CSF) is a glycoprotein growth factor that was originally identified as a product of activated T-Lymphocytes. Its primary function is to act on bone marrow cells via surface receptors and causes their growth and development.
It is also produced by fallopian tube and uterine cells and G-CSF receptors have been identified on the surface of egg cells. These findings prompted investigations that have shown its use to be of benefit in the treatment of implantation failure following IVF, recurrent miscarriage and poor development of the lining of the uterus during assisted reproduction treatment cycles that is resistant to other treatments.
Clinical trials using G-CSF as a treatment for thin endometrium have reported a clinically significant effect within 48 hours of administration. At Fertility North, we offer a form of G-CSF called Nivestim™ at a dosage that has been shown in clinical trials to be beneficial.
GIP is used to treat women that experience poor development of the lining of the uterus during assisted reproduction treatment cycles that is resistant to other treatments. The commonly accepted minimal endometrial thickness, at the end of the follicular phase, associated with conception, is 7mm.